

For the Quarter Ended March 31, 2026

Introduction

This Management Discussion and Analysis ("MD&A") provides information that management believes is relevant to an assessment and understanding of the Company's consolidated results of operation and financial condition. This discussion should be read in conjunction with the Consolidated Financial Statements for the year ended December 31, 2025 and the accompanying notes, which are prepared in accordance with International Financial Reporting Standards or "IFRS" and the Company's condensed consolidated interim financial statements for the period ended March 31, 2026. This discussion is based on information available to management as of May 14, 2026, unless otherwise indicated.

Unless otherwise indicated, all dollar amounts are expressed in Canadian dollars.

The core business of the Company is to provide advanced technology biological filters for removal of odors, volatile organic compounds (VOCs), hazardous air pollutants (HAPs) and for the conditioning of biogas renewable energy. With over 2,000 installed systems and over a decade of experience, the Company's groundbreaking biofilters are the technology of choice for wastewater treatment plants across North America. Additional information about the Company, including our most recently filed Annual Report, is available on SEDAR at www.sedar.com.

Forward Looking Statements

Certain statements in this report may contain "forward looking" statements that involve risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company or industry to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Words such as "may", "will", "expect", "believe", "plan", "intend", "should", "anticipate" and other similar terminology are used to identify forward looking statements. These statements reflect current assumptions and expectations regarding future events and operating performance and speak only as of the date of this MD&A, May 14, 2026. Forward looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to vary significantly from the results discussed in the forward looking statements, including, but not limited to, the factors discussed under "Risks and Uncertainties". Although the forward looking statements contained in this MD&A are based upon what management of the Company believes are reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward looking statements. These forward looking statements are made as of the date of this MD&A and the Company assumes no obligation, except as required by law, to update any forward looking statements to reflect new events or circumstances.

Non-IFRS Measures

“EBITDA,” “Order Bookings,” “Order Backlog” and “Working capital” do not have any standardized meaning prescribed by IFRS and may not be comparable to measures presented by other companies.

EBITDA is used to denote earnings (loss) from operations before interest, income taxes, foreign exchange gains and losses, depreciation and amortization. This measure is important to the Company since it is used by potential investors and lenders to evaluate the ongoing cash generating capability of the Company and thus the amounts they are willing to invest and lend to the Company.

Order Bookings and Order Backlog are non-IFRS measures that the Company uses to evaluate its sales performance. Order Bookings are those binding contracts that the Company enters into during a fiscal year with a third party for the delivery of our products or services. As Order Bookings are received, the contract value (before any associated sales taxes) is included in the Order Backlog. The Order Backlog is reduced by the revenue that is recognized on each project and is also adjusted for foreign exchange changes in the period presented.

Overview

Biorem is a leading clean technology company that designs, manufactures and distributes a comprehensive line of high-efficiency emissions control systems used to eliminate odors, volatile organic compounds (VOCs) and hazardous air pollutants (HAPs). Biorem also offers Biogas Conditioning technologies specializing in biological treatment of hydrogen sulfide.

Biorem offers a selection of products that can be tailored to suit application specific requirements. Biorem ensures optimized long-term performance on every application by custom-designing systems to meet the individual needs of their clients.

Biorem has sales and manufacturing offices across North America and in China, a dedicated research facility, a worldwide sales representative network, and a dedicated service and support division. As a result, Biorem has the resources available to ensure that projects are handled promptly and professionally from conception to completion.

The Company has more than 2,000 installed systems worldwide.

Significant Events For The First Quarter 2026

Key events of note in Q1 2026 include the following:

- Revenues for the quarter at \$6.8 million, were 44% higher than the same period in the previous year
- Order bookings for the quarter were \$18.7million
- Order backlog stood at a record \$77 million at the end of the quarter
- Net earnings for the quarter were \$201,000
- Working capital on March 31, 2026 stood at \$14.5 million

Selected Quarterly Information (Unaudited)

Selected Balance Sheet Information as at:

(in,000's)	March 2026	Dec 2025	Sept 2025	June 2025	March 2025	Dec 2024	Sept 2024
Cash	9,990	11,504	8,350	7,655	9,600	5,213	7,275
Accounts receivable	9,277	11,959	9,172	9,719	7,353	11,904	7,703
Unbilled revenue	2,906	3,236	2,965	2,463	2,791	2,964	2,157
Working capital	14,513	14,053	11,691	10,016	9,620	9,505	10,441
Total assets	31,544	33,576	27,780	27,101	28,173	28,511	24,377
Accounts payable	4,498	7,953	4,067	3,167	2,932	4,021	4,631
Accrued liabilities	2,038	1,837	744	1,124	2,132	2,438	1,910
Unearned revenue	5,596	4,589	7,152	815	7,561	6,372	3,460
Interest bearing loans	1,710	1,858	2,003	2,147	2,288	2,428	2,568
Shareholders' equity	15,297	14,926	12,196	10,945	10,692	10,625	9,955

Selected Statement of Operations information for the three month period ended:

(in,000's)	March 2026	Dec 2025	Sept 2025	June 2025	March 2025	Dec 2024	Sept 2024
Revenue	6,817	16,941	11,253	9,431	4,730	9,316	14,885
Cost of goods sold	5,425	11,000	8,087	6,881	3,621	7,718	9,864
Gross margin	1,392	5,941	3,166	2,550	1,109	1,598	5,021
Total operating expenses	1,085	2,212	1,553	1,496	1,016	1,311	1,992
Finance costs	36	39	38	41	44	47	47
Net earnings	201	2,677	1,158	745	37	168	2,192
EPS-basic	0.012	0.18	0.072	0.046	0.002	0.010	0.139
EPS-fully diluted	0.011	0.16	0.062	0.04	0.002	0.005	0.118
Common shares outstanding	16,134,737	16,134,737	16,005,087	16,029,227	16,137,437	16,137,437	15,799,727

All amounts except Working capital have been determined under IFRS.

Financial Results For The Three Months Ended March 31, 2026

The following analysis of the results of operations for the three months ended March 31 2026 includes comparisons to the three months ended December 31, 2025 and March 31, 2025.

Revenues

Revenues for the first quarter of 2026 were \$6.8 million, a \$2.1 million or 44% increase over the same period in the previous year but a large decrease from the \$16.9 million recorded in the previous quarter. Revenues in the first quarter are generally weaker than the rest of the year due to construction schedules.

Revenue by Geography

	March 2026	December 2025	March 2025
Canada	\$1,296,000	\$2,390,000	\$700,000
United States	4,531,000	8,861,000	3,019,000
Middle East	576,000	3,296,000	-
Other	414,000	2,394,000	1,011,000
Total Revenue	\$6,817,000	\$16,941,000	\$4,730,000

Biorem's core market is the North American municipal odour control market with international distribution established in Europe, the Middle East, Americas and South Africa as well as opportunistically in other jurisdictions. Project delivery mix varies from quarter to quarter but from the data it is evident that the Company relies heavily on the USA and Canada. The project mix in the current backlog of the Company is consistent with the geographic mix shown in the table.

A number of factors contribute to variations in the Company's quarterly results: customer scheduling and delivery of our products, the Company's mix of product and service offerings, the currency in which the revenue is earned and the timing of revenue recognition.

Bookings and Backlog

Order Bookings	Q1 2026	Q4 2025	Q1 2025
	\$18,700,000	\$13,300,000	\$16,700,000

Order Bookings are those binding contracts that the Company enters into with a third party for the delivery of our products or services. Bookings can vary considerably from quarter to quarter, due to both the size of the contracts won and the timing of the awarding of the contracts.

Bookings in the first quarter were \$18.7 million, which was \$5.4 million greater than the previous quarter and \$2 million or 12% over the same period in the prior year. 18 new projects were booked in the quarter, with orders originating from Canada the United State and the Middle East. The

Company's bidding activity during the quarter and subsequent to the quarter continues to be robust with the Company's outstanding bids at historic highs.

Order Backlog	March 2026	December 2025	March 2025
	\$77,000,000	\$65,300,000	\$68,100,000

The value of the Company's order backlog at March 31, 2026 stood at a historic \$77 million a \$12 million increase over the value of the backlog on December 31, 2025 and \$9 million higher than the \$68 million order backlog on March 31, 2025. The increase in the value of backlog between December 31, 2025 and March 31, 2026 was largely the result of the \$18 million in new orders received during the quarter plus the delays of some project deliveries into Q2 and Q3.

Due to customer scheduling, the Company cannot provide precise guidance as to the quarters when the Backlog will be converted into revenue however management's current estimate is that the majority of the Backlog will be converted into revenue during the next 18 months.

Gross Profit and Operating Expenses

Gross Profit	March 2026	December 2025	March 2025
	\$1,392,000	\$5,941,000	\$1,110,000

Gross profit of \$1.4 million in the quarter represents a increase of \$282,000 over the same quarter in the previous year but a \$4.5 million decrease from the \$5.9 million record in the previous quarter. The significant variation in gross profit between the quarters is directly related to the variation in the revenue reported in the respective quarters. Gross profit percentage was 20% of revenue compared to 35% for the quarter ended December 31, 2025 and 23% for the three months ended March 31, 2025.

The fixed component of cost of goods sold which includes engineering and project management was \$1.2 million compared to \$1.1 million in the first quarter of 2025.

Sales and Marketing	March 2026	December 2025	March 2025
	\$757,000	\$1,387,000	\$565,000

The Company's sales and marketing expenditures are composed of two significant categories; variable selling costs and sales department expenditures.

Variable selling costs represent amounts that are paid to both internal sales employees and external manufacturer representatives. These costs are incurred when the project revenue is recognized during the period. Sales department expenditures relate primarily to departmental salaries and advertising expenses.

Sales and marketing costs for the first quarter of 2026 totaled \$757,000 and represented 11.1% of revenue compared to the 8.3 % of revenue that sales and marketing costs represented for the

2025 fiscal year. The increase in the ratio of sales costs to revenue in Q1 compared to the prior year is due the component of fixed sales costs over lower revenue reported.

Research and Development	March 2026	December 2025	March 2025
	\$10,000	\$31,000	\$14,000

Research and Development expenditures include research and development salaries, material and laboratory costs as well as subcontractor costs for the development of and installation of demonstration sites.

General and Administrative	March 2026	December 2025	March 2025
	\$440,000	\$684,000	\$457,000

General and Administration expenditures include administrative salaries, consulting, office supplies, regulatory and transfer fees, travel and corporate affairs.

General and administrative expenses of \$440,000 for the first quarter of 2026 were virtually unchanged from the \$457,000 in the same period in the prior year.

Other Expense(Income)	March 2026	December 2025	March 2025
	\$(123,000)	\$119,000	\$(21,000)

Other income in the quarter was from \$123,000 of foreign exchange gains on the monetary assets of Biorem Technologies Inc held in US dollars compared to \$119,000 of foreign exchange losses in the fourth quarter of 2025, and \$21,000 of foreign exchange losses in the first quarter of 2025. All the gains and losses were the result of fluctuations the exchange rate of the United States dollar to the Canadian dollar during the periods.

Liquidity

The Company finances its operations and capital expenditures through cash generated from operations and equity and debt financings.

2026 Cash flow

Cash	March 2026	December 2025	March 2025
	\$9,990,000	\$11,505,000	\$9,600,000

Cash on hand decreased by \$1,515,000 to \$9,990,000 on March 31, 2026 from \$11,505,000 on December 31, 2025.

The sources and uses of cash for the quarters ended are summarized below:

	March 2026	December 2025	March 2025
Cash provided by (used in) operating activities	\$(1,129,000)	\$2,533,000	\$4,695,000
Cash provided by (used in) investing activities	(271,000)	(28,000)	(91,000)
Cash provided by (used in) financing activities	(186,000)	(136,000)	(206,000)
Foreign exchange gain (loss) on cash	71,000	812,000	(11,000)
Net increase (decrease) in cash	\$(1,515,000)	\$3,182,000	\$4,387,000

Cash provided by operating activities – Earnings from operating activities during the quarter generated \$395,000 of cash, and \$1,524,000 of cash was used to fund increases in non-cash working capital. In particular, \$3,497,000 was used to reduce accounts payable, and \$1,169,000 was used to fund an increase in purchase deposits and \$944,000 to fund an increase in inventories. These uses of cash were offset by \$3,167,000 of cash generated from a reduction of accounts receivable and a \$982,000 increase in unearned revenue.

Cash used in investing activities – The Company invested \$271,000 in the quarter in media manufacturing equipment.

Cash used by financing activities – \$147,000 was used to make principal payments on the Company's term loan during the quarter and a further \$38,000 of cash was used in the quarter to pay lease obligations.

Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they are due. The Board of Directors reviews and approves the Company's operating and capital budgets, as well as any material transactions out of the ordinary course of business including proposals on major investments. The Company manages liquidity risk by maintaining adequate reserves, banking facilities and by continuously monitoring forecasts and actual cash flows and matching the maturity profiles of financial assets and liabilities.

The Company's objectives of managing liquidity risk are to forecast the liquidity position as accurately as possible and to maintain sufficient resources to pursue its growth strategy. The Company's financial liabilities include accounts payable and accrued liabilities, unearned revenue and contract advances as well as long and short term debt.

The Company's net current assets (liabilities) are summarized below.

	March 2026	December 2025	March 2025
Cash	\$9,990,000	11,505,000	\$9,600,000
Working capital	14,513,000	14,053,000	9,620,000
Unused operating line of credit	3,000,000	3,000,000	\$3,000,000

(1) Working capital represents total current assets less total current liabilities.

A maturity analysis as at March 31, 2026 of the Company's financial liabilities based on gross, undiscounted cash flows is presented below. The maturity analysis is based on the earliest date that liabilities may be due.

	Carrying Amount \$	Contractual Cash Flow \$	Less than 1 year \$	1-5 years \$	5+ years \$	Total \$
March 2026						
Accounts payable	4,498,136	4,498,136	4,498,136	-	-	4,498,136
Accrued liabilities	2,038,176	2,038,176	2,038,176	-	-	2,038,176
Interest bearing loans	1,710,686	1,811,535	658,740	1,152,795	-	1,811,535
Lease liabilities	939,152	1,258,693	155,672	640,533	462,488	1,258,693
	<u>9,186,150</u>	<u>9,606,540</u>	<u>7,350,724</u>	<u>1,793,328</u>	<u>462,488</u>	<u>9,606,540</u>
December 2025						
Accounts payable	7,953,381	7,953,381	7,953,381	-	-	7,953,381
Accrued liabilities	1,837,018	1,837,018	1,837,018	-	-	1,837,018
Interest bearing loans	1,857,907	1,976,221	658,740	1,317,481	-	1,976,221
Lease liabilities	973,858	1,273,068	153,164	624,976	494,928	1,273,068
	<u>12,622,164</u>	<u>13,039,688</u>	<u>10,602,303</u>	<u>1,942,457</u>	<u>494,928</u>	<u>13,039,688</u>

Capital Resources

The Company currently does not have any undrawn debt facilities. The Company does not have any significant capital expenditure projects underway or forecasted in 2025.

Financial instruments

At March 31, 2026 the Company held no forward exchange contracts.

Commitments

Commitments include operating leases for office equipment and facilities, bank guarantees, and performance bonds issued on our behalf by financial institutions in connection with facility leases and contracts with public sector customers. Aside from the aforementioned, the Company does

not have any other business arrangements or any equity interests in unconsolidated companies that would have a significant effect on its assets and liabilities as at March 31, 2026.

Off-Balance Sheet Arrangements

As a general practice, the Company does not enter into off-balance sheet financing arrangements. Except for operating leases and letters of credit, all commitments are reflected on the balance sheet.

Transactions with Related Parties

The Company did not have any material related party transactions during the three months ended March 31, 2026.

Outstanding Share Data

	March 31 2026	December 31 2025	March 31 2025
Common shares	16,117,027	16,117,027	16,137,437
Employee stock options (1)	3,300,000	3,300,000	3,295,000
	19,417,027	19,417,027	19,432,437

(1) Assumes 100% conversion of outstanding options

There have been no material changes to the Company's outstanding share data from March 31, 2026 to the date of this MD&A.

Significant Accounting Policies and Estimates

The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related contingent assets and liabilities. On an on-going basis, management evaluates the estimates including those related to long-term revenue contracts, intangible assets, goodwill, bad debts, warranty obligations and income taxes. The estimates are based on historical experience and on various other factors that are believed to be reasonable in the circumstances. Actual results may differ from these estimates. The following critical accounting policies include those which involve management's more significant judgments and estimates:

- a) Revenue recognition: The Company derives revenue from long-term contracts which require performance over a time span which may extend beyond one or more accounting periods. The Company recognizes revenue on long-term contracts using the percentage-

of-completion method, based on costs incurred relative to the estimated total contract costs. Management has concluded that costs incurred are the best available measure of progress toward completion of these contracts. Estimated total direct contract costs is subjective and requires the use of our best judgments based upon the information we have available at that point in time. Management's estimate of total direct contract costs has a direct impact on the revenue recognized by the Company. Changes in estimates are reflected in the period in which they are made and would affect revenue and cost of sales and unbilled or unearned revenue.

The Company also provides for estimated losses on incomplete contracts in the period in which such losses are determined.

- b) **Deferred income taxes:** Deferred income tax assets are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment. The income tax bases of assets and liabilities are based upon the interpretation of income tax legislation across various jurisdictions. The deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing for reversal of temporary differences as well as possible audits of tax filings by the regulatory authorities. In accessing the realizability of deferred income tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. The Company has recorded deferred tax assets as at March 31, 2026 of \$454,000.
- c) **Investment tax credits:** In the normal course of operations, the Company's Scientific Research & Experimental Development (SR&ED) expense claims are subject to review by federal and provincial government authorities.
- d) **Warranty obligations:** Management routinely assesses and adjusts for its anticipated warranty costs based on experience and estimates of the potential warranty obligations for its installations.
- e) **Expected credit losses:** Management routinely reviews accounts receivable and sets up a reserve for expected credit losses. This is an estimate since some of the reserved accounts may be collected and we may subsequently find that some accounts currently deemed collectible become uncollectible. As well, the estimated present value of future

cash flows associated with the outstanding accounts receivable is determined and an impairment loss is recognized for the difference between this amount and the carrying amount as follows: the carrying amount of the asset is reduced to estimated present value of the future cash flows associated with the asset, discounted at the financial asset's original effective interest rate, either directly or through the use of an allowance account and the resulting loss is recognized in the consolidated statement of operations for the period. In a subsequent period, if the amount of the impairment loss related to financial assets measured at amortized cost decreases, the previously recognized impairment loss is reversed through the consolidated statement of operations to the extent that the carrying amount of the investment at the date the impairment is reversed does not exceed what the amortized cost would have been had the impairment not been recognized. The assumptions used for this estimate, which are based on the Company's historical collection history, are presented in Note 8 to the December 31, 2023 financial statements.

- f) Long lived assets: Management reviews the carrying value of long lived assets including plant and equipment and amortizable intangible assets for impairment to determine if the carrying value of an asset may not be recoverable due to changes in the current and expected future use of the asset, external valuations of the asset, and the obsolescence or physical damage to the asset. If such indicators of impairment exist, the asset's recoverable amount is estimated. An impairment loss is recognized if the carrying amount of an asset or its related cash generating unit exceeds its estimated recoverable amount.
- g) Compound financial instruments: The financial liability component of a compound financial instrument is recognized initially at the fair value of a similar liability that does not have an equity conversion option. The equity component, representing the holders' option to convert into common shares, is recognized initially at fair value determined as the excess of the face value of the compound financial instrument and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is included within contributed surplus and is not re-measured subsequent to initial recognition.
- h) Leases: On January 1, 2019 the Company adopted IFRS 16 Leases which requires assets and liabilities arising from all leases with some exceptions to be recognized on the statement of financial position. The Company has applied IFRS 16 using the modified retrospective approach and therefore the comparative information has not been restated and continues to be reported under IAS 17.

At inception of a contract, the Company assesses whether a contract is, or contains a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

At inception of a contract that contains a lease component, the Company allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. The Company recognizes a right-of-use asset.

- i) There were no new accounting policies adopted during the period.

Outlook

Bidding activity in 2026 has been robust and at historically high levels. This has translated into a strong booking quarter and record backlog to start the 2026 year. Efforts to rebuild aging infrastructure in North America as well as treatment capacity expansion continue to be the driving forces for this momentum. There is strong market demand for BIOREM's engineered solutions for air emissions abatement predicted over the medium to long term.

Biorem's latest product lines continue to gain market traction. Physical and chemical technologies, sound attenuation, and degasification systems are all maturing at accelerated rates. Market response has been positive and adoption robust. Investments made in 2025 into the Biorem service group are expected to continue to generate significant contributions to recurring revenue in 2026.

Given the current geopolitical climate, inflationary pressures and some supply chain disruptions are expected to continue to be challenges for the next twelve to eighteen months. The Company has managed to deal effectively with these challenges during the previous several years and management continues to be vigilant and proactive in responding to these factors. Of particular concern are delays expected with contract award, engineering submittal review and field construction schedules.

Risks and Uncertainties

Liquidity risk

At March 31, 2026 the Company had working capital of \$14.5 million and a \$3 million unused operating line of credit from a Canadian chartered bank. Management believes the Company has sufficient working capital to meet all of its operational needs.

Sales Cycle

The Company's long sales cycle may cause revenue fluctuations period over period – since operating expenses are largely based on anticipated revenue trends and a significant portion of expenses are, and will continue to be, fixed, any delay in generating or recognizing revenues could negatively impact our business, operating results, financial condition or prospects.

Order Backlog

As of March 31, 2026 the Company's Order Backlog was \$77 million. However, the expected future revenue from the Company's Order Backlog may not be realized or, if realized, may not result in net earnings. Projects could remain in Order Backlog for an extended period of time. In addition, project cancellations or scope adjustments may occur from time to time with respect to contracts reflected in the Company's Order Backlog. Cancellation or delay of contracts may have a material adverse effect on our financial status.

Delays or Defaults in customer payments affecting liquidity

Due to the nature of our contracts, at times we commit resources to projects prior to receiving payments from our customers in amounts sufficient to cover expenditures as they are incurred. Delays in customer payments may require us to make a working capital investment. If a customer defaults in making payments on a project to which we have devoted significant resources, it could have a material negative effect on our liquidity as well as the results from operations.

Reputation

The Company's reputation for technical expertise, high level of service and the lower life cycle cost of products compared to our competitors products is one of our most valuable business development assets. The loss of this reputation due to client dissatisfaction represents a risk to our ability to win additional business both from existing clients and from future clients.

Patents and Proprietary Right

The Company relies on a combination of patents, trademarks, trade secrets and knowledge to protect its proprietary technology and rights. There can be no assurance that the Company's patents will not be infringed upon, that the Company would have adequate remedies for any such infringement, or that its trade secrets will not otherwise become known or independently developed by its competitors. There can also be no assurance that any patents now or hereafter issued to, licensed by or applied for by the Company will be upheld, if challenged, or that the protections afforded thereby will not be circumvented by others.

Dependence on Subcontractors

The Company does not directly engage in field construction but relies on field construction subcontractors operating under the supervision of the Company's employees. The unavailability of field construction subcontractors, or a substantial increase in pricing by a significant number of these subcontractors could adversely affect the Company. In addition, failure of subcontractors to properly perform work that has been subcontracted to them could adversely affect the Company by increasing the costs to the Company of completing a project and by damaging the Company's reputation.

Product Liability

If there are defects in our systems or if significant reliability, quality or performance problems develop with respect to our systems, there may be a number of negative effects on our business. Our products are often installed in corrosive or flammable environments. The Company carries product liability insurance, which includes coverage for sudden or accidental pollution impact. It is possible that a customers' inability to comply with applicable pollution control laws or regulations stemming from failure or non-performance of the Company's products or systems may subject the Company to liability for any fines imposed upon such customer by regulatory authority or for damages asserted to have been incurred by any third party adversely affected.

Competition

Virtually all contracts for the Company's products are obtained through competitive bidding. Although the Company competes on technical expertise, reputation for service and lower life cycle cost, there can be no assurance that the Company will maintain its competitive position in its principal markets.

Fixed Price Contracts may result in losses

The Company's receipt of a fixed price contract as a consequence of being the successful bidder carries the inherent risk that the Company's actual performance cost may exceed the estimates upon which its bid was based. To the extent that contract performance costs exceed projected costs, the Company's profitability could be materially affected.

Foreign Exchange

The Company is subject to risk of exchange rate fluctuations related to anticipated revenues, Order Backlog and existing assets and liabilities denominated in currencies other than Canadian dollars. At March 31, 2026, the Company had US dollar denominated net monetary assets of \$8,090,000.

Stock Trading Volume is low

The monthly average trading volume of the BIOREM common shares on the Toronto Venture Exchange during 2025 was 1.2 million shares. Due to the low trading volume the price of the common shares could be subject to wide price fluctuations in response to business development announcements, competitors, quarterly variations in operating results, and other events or factors.

Risk to Product Development

Corporate resources are currently being expended on the development of the new media technologies. These technologies are constantly in development and have not yet been fully commercialized. There can be no guarantee that the new media technology will achieve the

performance criteria which the Company believes is necessary for it to be a successful product in the market. In addition, there are risks associated with commercializing any product including the risk that full scale production may not be achieved at an acceptable cost level. Failure to successfully commercialize the new media technologies may materially and adversely affect the Company's financial condition and results of operations.

Acceptance of new products by the Market

Market risk exists for new products such as the new media. There is no assurance that new products will be accepted by the market, that desired volumes will be realized over the product life or that the product life will not be shorter than expected due to product obsolescence. New products that are launched by the Company's competitors may also have price or other advantages over the Company's products. In addition, new product offerings may also require more significant marketing and sales efforts to gain market acceptance.

Dependency on key personnel

The success of the Company is dependent upon the attraction and retention of highly skilled personnel in a number of key areas including management positions. The unexpected loss or departure of any of the Company's key officers or employees could have a material adverse effect on the future operations of the Company. The success of the Company's business will depend, in part, upon the Company's ability to attract and retain qualified personnel as they are needed. There can be no assurance that the Company will be able to engage the services of such personnel or retain its current personnel.